Reduction in self-harming behaviour after zuclopenthixol decanoate

Abstract

No psychotropic drug is specifically licensed for the management of emotionally unstable borderline personality disorder. Prescribing 'off-label' places additional responsibilities on the prescriber and may increase liability if there are adverse effects. This case report describes a patient with borderline personality disorder who was started on zuclopenthixol decanoate with successful outcome in terms of reducing self-harming behaviour and impulsivity. © 2014 John Wiley and Sons, Ltd.